Back to News
Market Impact: 0.4
Iovance Maps TIL Therapy Expansion After Record Revenue and Margin Gains
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany FundamentalsProduct Launches
Iovance Biotherapeutics reported a record second quarter, generating nearly $100 million in revenue and a 56% margin. The company is expanding its tumor-infiltrating lymphocyte (TIL) therapy platform into multiple solid-tumor indications, supporting a stronger commercial and pipeline outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
IOVA0.85
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- Berkshire-owned utility’s wildfire lawsuits head to Oregon Supreme Court
- McDonald's is about to report earnings. Here's what to expect